CD79B and diffuse large B-cell lymphoma: Pre-clinical data show polatuzumab vedotin is active against several diffuse large B cell (DLBCL) lines including activated B cell (ABC) and germinal center B cell like (GCB) subsets, and those with CD79b mutations that predominantly occur in ABC DLBCL patients who have poor survival [47].